Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

Trial Details

NCT ID
NCT06915753
Phase
PHASE1
Sponsor
Tyra Biosciences, Inc
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • TYRA-430
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Francisco, California, United States|37.77493,-122.41942
  • Stanford, California, United States|37.42411,-122.16608
  • Westwood, Kansas, United States|39.04056,-94.6169
  • Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

  • All Patients:
  • Age ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.
  • Adequate end organ function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →